GLP-1s in Psychiatry: Beyond Weight Loss - PsyQ Episode 5

This episode, we delve into the rapidly evolving landscape of GLP-1 receptor agonists in psychiatry. We'll critically appraise Hendershot et al.'s (2025) JAMA Psychiatry study on once-weekly semaglutide for Alcohol Use Disorder, examining its efficacy in reducing alcohol consumption and craving in a randomized clinical trial. We then broaden our scope with Pierret et al.'s (2025) systematic review and meta-analysis in JAMA Psychiatry, which assesses the psychiatric safety profile and quality of life outcomes associated with GLP-1 RA treatment. Finally, we integrate insights from the Carlat Psychiatry Report (Aiken & Liebers, 2025) on "New Weight Loss Drugs in Psychiatry," exploring mechanisms, potential applications for antipsychotic-induced weight gain, binge eating disorder, mood, and cognition, alongside crucial risk considerations. Join us as we synthesize these findings and discuss their clinical implications for psychiatric practice.Sources:Hendershot CS, et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry.Pierret ACS, et al. (2025). Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis. JAMA Psychiatry.Aiken C & Liebers D. (2025). New Weight Loss Drugs in Psychiatry. The Carlat Psychiatry Report. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit upathak.substack.com